Group items tagged

Pfizer said on Thursday (June 1) data from late-stage trials showed its experimental combination of antibiotics was effective in treating deadly infections caused by drug-resistant bacteria. Deaths from antibiotic-resistant bacteria, also known as superbugs, have been on the rise globally, and health regulators have called for the development of newer treatments as resistance to older antibiotics grows. The late-stage studies compared the experimental combination of the antibiotics aztreonam-avibactam (ATM-AVI) and existing generic drug metronidazole with a combination of two older antibiotics - meropenem and colistin - to treat complicated intra-abdominal infections and types of hospital-acquired pneumonia. Hospital-acquired pneumonia occurs in patients at least two to three days after being admitted, or in those who have life-threatening lung infections with high mortality rates and who are on mechanical breathing machines. Pfizer said the data from the studies shows the antibiotic combination of ATM-AVI is effective and well-tolerated in treating infections caused by gram-negative bacteria. The cure rate in patients with complicated intra-abdominal infections with Pfizer's combination therapy, along with existing generic drug metronidazole, was 76.4%, versus 74% using the other antibiotics.

Pneumonia is a formidable respiratory infection that affects millions of people yearly. It remains a global health concern. Thankfully, science has armed us with an impressive arsenal against this potentially life-threatening condition: the pneumonia treatment antibiotics.

Pleurisy and pneumonia pain are respiratory conditions that can cause chest discomfort, but the location, causes, and pain symptoms can vary. In this comprehensive guide, we will explore the pain associated with pleurisy and pneumonia, helping you understand these conditions and seek appropriate medical care.

What Is Immunity? Immunity is the capability of an organism to sustain the "self" molecules that constitute its own body and to resist and destroy the "nonself" molecules which have their origin from toxins and infectious microorganisms. With increase in age, our immune response capability weakens and hence we become susceptible to respiratory infections like influenza, Covid-19, pneumonia and cancer. Nutrition and immunity are related to each other in the elderly people. Micronutrient malnutrition is a condition in which a person is deficient of some important essential vitamins and minerals as he or she eats less and often has less variety in the diet. They do not acquire the essential amounts of zinc, iron, folic acid, selenium, copper, vitamins A, B6, C, and E. If there is no time to prepare healthy daily diet, dietary supplements will surely help the older people to maintain a healthy immune system. Everyone Says Immunity! Really What Is Immunity Multimix from Indo French Lab is the best herbal tonic for all age groups, especially the elderly people. It maintains proper functioning of the lungs. It clears the respiratory system and gets rid of cough and cold. It increases the oxygen intake of your body and strengthens the lungs. There are many other healthcare products available at Indo French Labs.

The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future. It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they need them the most. The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot. Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used. By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics, decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.

GlaxoSmithKline on Tuesday (May 31) snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm. The London-listed company has agreed to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones for Affinivax. "GSK plc today announced that it has entered into a definitive agreement to acquire Affinivax, Inc," it said in a statement. "Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines," it added. The Cambridge, Massachusetts-based firm specialises in vaccines for diseases including meningitis, pneumonia and bloodstream infections. "The proposed acquisition further strengthens our vaccines research and development (R&D) pipeline, provides access to a new, potentially disruptive technology, and broadens GSK's existing scientific footprint in the Boston area," said GSK's chief scientific officer Hal Barron.

Pharmaceutical giant GlaxoSmithKline aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults. RSV is a leading cause of pneumonia in toddlers and the elderly, but the complex molecular structure of the virus and safety concerns have stymied efforts to develop a vaccine since the virus was first discovered in 1956. Companies including Pfizer, J&J, Sanofi, Moderna and AstraZeneca are also racing to get an RSV therapy or vaccine approved. The latest GSK trial is the first to show statistically significant efficacy for RSV in adults aged 60 years and older, the British drugmaker said of the ongoing study on Friday (June 10). If approved, the RSV vaccine is expected to generate billions for GSK, which is already the world's biggest vaccine maker by sales but has faced pressure from activist investors such as Elliott Management who have urged the London-based company to shore up its drug pipeline.

The NHS has signed the first-of-its-kind subscription deal for two antimicrobial drugs - cefiderocol and ceftazidime-avibactam, manufactured by Shionogi and Pfizer respectively - that will help around 1700 patients per year with severe bacterial infections. Under this deal, pharmaceutical firms will receive a fixed yearly fee - capped at a level that represents value to taxpayers - in order to incentivise funding for innovation that can generate a pipeline of new antibiotics for NHS patients. NHS said the deal will help patients with serious infections that have evolved so much that antibiotics and other current treatments are no longer effective can be given a potentially life-saving alternative. The drugs will provide a lifeline to patients with life-threatening infections like sepsis, hospital or ventilator pneumonia and blood stream infection. Announcing the deal at NHS ConfedExpo, NHS Chief Executive Amanda Pritchard called the revolutionary subscription deal a game-changer and the latest NHS success in using its commercial power to benefit NHS patients in line with the NHS Long Term Plan. "Superbug-busting drugs on the NHS will save lives and strike a blow in the global battle against antimicrobial resistance," Pritchard said.

In a collaborative effort, the National Health Services England (NHSE) is set to deliver the RSV(respiratory syncytial virus) vaccination programme where pharmacists alongside other healthcare professionals will play a crucial role in administering the vaccine. The UK Health Security Agency has announced the launch of the new vaccination programme targeting the respiratory syncytial virus (RSV), set to begin on 1 September 2024. Along with GPs, NHS England (NHSE) will "commission a number of community pharmacies to deliver the programme", ensuring broad accessibility and coverage to protect two high-risk groups: older adults and pregnant women. RSV is an RNA virus related to mumps, measles, and human parainfluenza viruses. It commonly causes coughs and colds in winter, transmitted through droplets and secretions from close contact with infected individuals. While most RSV infections are mild, infants under six months and the elderly are particularly susceptible to severe diseases like bronchiolitis and pneumonia, which can lead to hospitalisation.

Large collection of healthcare innovations focused on AIDS and HIV.

The nation's worst hospitals treat twice the proportion of elderly black patients and poor patients than the best hospitals, and their patients are more likely to die of heart attacks and pneumonia, new research shows.

Tynor Leg Traction Brace is basically designed to provide traction to the leg. It works well even on the weak or geriatric skin. It ensures proper compression of the leg and provides traction. It is made of three layered polyurethane fabric which makes it soft and comfortable to use. The innermost layer gives the required friction for faster recovery. It is augmented with hook and loop closures to make it convenient to put on and remove. It does not require any adhesion. It provides cushion like support to the leg and relieves it from pain. It also prevents the bone from getting fractured and any muscle pull. It does not cause any peeling of skin and any rash or allergy on skin. It distributes the pressure exerted on the leg evenly. Tynor Leg Traction Brace Leg traction brace is a traction halter applied to the leg for below knee traction. It offers a distinct advantage of a very large holding surface area, ease of application and removal, reuse and patient comfort. Easy application & removal. Can be used for geriatric/ weak skin. Ideal for sensitive skins. Easy monitoring. Distributes pressure evenly. Tynor Leg Traction Brace Features Three-layered PU bonded fabric offers: Soft feel and plush looks through the top layer. Comfortable cushioning through the middle Polyurethane layer. Inner layer provides good frictional characteristics. Multiple hook loop closures Ensure controlled compression. Easy application and removal No loosening, less monitoring Large skin contact area Ensures no vaso-constriction. Eliminates need of an adhesive. Convenient and quick to apply Ensures no skin peeling. Ideal for weak or geriatric skins Tynor Rib Belt Rib belt is applied to the thoracic and upper abdominal region to compress and bind the rib cage during rib fractures and postoperative care, while allowing sufficient flexibility for comfortable breathing. Extra porous. With splinting pad. No buckling or rolling over. Controlled compression

Pharmadoctor, a company which provides clinical service packages to pharmacists, has announced the launch of the UK's first private Covid vaccination service via its nationwide network of partner community pharmacies. For the first time, people who are eligible for the Covid-19 vaccine (those aged 12 years and over) will be able to get the shots from their local independent pharmacy by paying as little as £45 per jab, the company said. The delivery of the new service is expected to start by 1st April at the latest by "thousands of pharmacists" using the Pharmadoctor eTool. To encourage pharmacists to sign up early to provide the service, the company is offering its package at half-price until 31st March.